The paradigm that microtubule-targeting agents (MTAs) cause cell death via mitotic arrest applies to rapidly dividing cells but cannot explain MTA activity in slowly growing human cancers. Many preferred cancer regimens combine a MTA with a DNA-damaging agent (DDA). We hypothesized that MTAs synergize with DDAs by interfering with trafficking of DNA repair proteins on interphase microtubules. We investigated nine proteins involved in DNA repair: ATM, ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1, and p63. The proteins were sequestered in the cytoplasm by vincristine and paclitaxel but not by an aurora kinase inhibitor, colocalized with tubulin by confocal microscopy and coimmunoprecipitated with the microtubule motor dynein. Furthermore, adding MTAs to radiation, doxorubicin, or etoposide led to more sustained γ-H2AX levels. We conclude DNA damage-repair proteins traffic on microtubules and addition of MTAs sequesters them in the cytoplasm, explaining why MTA/DDA combinations are common anticancer regimens. (1, 2) . Although this explanation applies to rapidly dividing cells in preclinical models, it cannot explain the activity of these agents in tumors in humans because these cells divide much more slowly. For the latter situtation, a different paradigm must explain the activity of MTAs, and we have proposed that interfering with microtubule (MT) trafficking in interphase cells is the principal mechanism of MTA action (3) (4) (5) . In breast, ovarian, lung, and head and neck cancers, as well as in most lymphomas, combination regimens that include a MTA and a DNA-damaging agent (DDA) are preferred (Table  S1 ). Although the frequency with which these combinations are used might be fortuitous, it is likely there is a mechanistic basis for this outcome. We hypothesized that by hampering the trafficking of essential DNA repair proteins, MTAs synergize with DDAs, augmenting their toxicity. To explore this theory further we studied the effects of combining a MTA and a DDA in a number of cell models and examined the distribution and biology of nine different proteins involved in DNA repair. We have confirmed the hypothesis and report our findings.
Results
Vincristine Increases Cytoplasmic Retention of Eight DNA DamageRepair Proteins in A549 Cells. We began by testing our hypothesis that proteins involved in the repair of DNA damage traffic from the cytoplasm to the nucleus on MTs. If true, one would expect treatment with a MTA, such as vincristine, to affect their intracellular distribution. In these and all other experiments we chose noncytotoxic drug concentrations, allowing us to examine viable cells. We examined eight proteins that repair DNA damage (ATM, ATR, DNA-PK, Rad50, Mre11, p95NBS1, p53, and 53BP1), choosing them from a larger number initially considered based on the availability of commercial antibodies that performed well on immunoblots and immunofluorescence in A549 cells. We treated A549 cells with vincristine or doxorubicin alone or in combination, and examined the intracellular distribution of the eight proteins both in the absence of any DNA damage or after doxorubicin-induced DNA damage (primarily to induce p53 levels), cognizant that all of these proteins might not be involved in the repair of doxorubicin-induced DNA damage. As shown in Fig. 1 , for all eight proteins, the percentage in the cytoplasm was greater in cells treated with either vincristine alone or vincristine in combination with doxorubicin, compared with those treated only with doxorubicin or not treated at all. The fold-increase in cytoplasmic retention was consistently approximately two-to sevenfold, confirming a role for MTs in the Significance Drugs targeting microtubules are among the most active anticancer agents. In vitro and in preclinical models, these agents are said to interfere with mitosis. However human tumors divide too slowly for this paradigm to apply, evidenced by the failure of over a dozen well-designed antimitotic agents targeting the aurora kinases and kinesin spindle protein that had minimal antitumor activity but caused severe bone marrow suppression. We have proposed that microtubule-targeting agents interfere with the trafficking of critical proteins in interphase microtubules. If true, then one must identify critical proteins whose traffic on microtubules is impacted. We identify nine DNA repair proteins that traffic on microtubules, explaining why combinations of a microtubule-targeting agent and a DNA-damaging agent are frequently used in cancer therapy.
Author contributions: M.S.P., E.K.-P., S.T., D.S., U.G., and A.T.F. designed research; M.S.P., E.K.-P., S.T., M.R., X.Z., T.K.M., R.R., and M.B. performed research; Y.P. and D.S. contributed new reagents/analytic tools; M.S.P., E.K.-P., S.T., J.W., M.R., X.Z., T.K.M., R.R., M.B., D.S., U.G., and A.T.F. analyzed data; M.S.P. and A.T.F. wrote the paper; U.G. supervised research and data analysis; and A.T.F. supervised research. trafficking of DNA damage-repair proteins to the nucleus and demonstrating the vulnerability of this transport process to a MTA. Similar results were obtained in four nonadherent Burkitt's lymphoma cell lines (CA46, DG-75, Ramos, and ST486) with increased cytoplasmic retention of 53BP1 observed with vincristine plus doxorubicin or vincristine alone, compared with doxorubicintreated cells or the untreated control (Fig. S1 ).
Neither the Aurora Kinase Inhibitor, VX680, Nor Serum Starvation Affect the Cellular Distribution of DNA Damage-Repair Proteins. To confirm that the increase in cytoplasmic retention of DNA damage-repair proteins after treatment with a MTA was a result of impaired MT trafficking and not mitotic arrest or possibly nuclear membrane disruption, we conducted the additional experiments shown in Fig. 2 . We (i) treated A549 cells with the aurora kinase inhibitor (AKI), VX680, and (ii) serum-starved SKOV3 cells to reduce the fraction of cells arresting in mitosis after vincristine. As shown in Fig. 2A , compared with control cells, both VX680 and vincristine induced similar G 2 M arrest, allowing us to address the effect of cell cycle arrest on the cellular distribution of the proteins. As shown in Fig. 2B and tabulated below the figure, compared with vincristine, VX680 had no effect on the cellular distribution of the eight proteins, excluding the possibility of cell cycle arrest as the etiology of the altered cellular distribution and supporting interference of protein trafficking on MTs as the cause of cytoplasmic sequestration. Similar results are shown in a separate experiment in Fig.  2C and these are compared with the effect of another MTA, paclitaxel. As in Fig. 2B , VX680 (AKI) has no effect on the nuclear/cytoplasmic distribution, whereas paclitaxel, like vincristine, resulted in increased cytoplasmic retention of several DNA damage-repair proteins. Additionally, we compared the cellular distribution of the DNA damage-repair proteins in SKOV3 cells that either were treated with serum or deprived of serum for 48 h, the latter to slow transition through the cell cycle before treatment with vincristine. We chose SKOV3 cells because their course through the cell cycle can be slowed by serum starvation (6) . As shown in Fig. 2D , with or without serum we observed similar cytoplasmic/nuclear distribution before and after vincristine for four DNA damage-repair proteins that could be reliably detected with our antibodies in the SKOV3 cells. The distributions were similar despite fewer cells in mitosis in serum-starved cells (Fig. 2E ), indicating the outcome was independent of the fraction of cells in mitosis. In these as in all experiments, distribution of all cytoplasmic and nuclear marker proteins were unaffected by alterations in cell cycle phases and indicate the lack of measurable contamination of the fractions.
Immunofluorescence Demonstrates Colocalization of DNA DamageRepair Proteins and MTs. To provide additional evidence for an interaction between the DNA damage-repair proteins and MTs, we performed confocal microscopy on untreated A549 cells fixed and incubated with antibodies to one of the DNA damage-repair proteins followed by an antitubulin antibody. As shown in Fig. 3 , colocalization with MTs was observed for DNA-PK, p95NBS1, Mre11, 53BP1, p53, and p63 proteins, often seen to be linear and punctate along MTs; and except for p63, the proteins also localized prominently to nuclei. Antibodies against ATM and ATR did not perform well by immunofluorescence, precluding definitive conclusions. This association occurs only with intact MTs and not soluble tubulin (after vincristine treatment) nor the MT bundles that occur following paclitaxel (results with DNA-PK, Mre11, 53BP1, and p53 after vincristine and paclitaxel are shown in Fig. S2 ). Additionally, gelsolin, used as a control protein that neither associates with nor traffics on MTs and does not appear in the nucleus, localized to actin and the cytoplasm and had neither MT nor nuclear localization (Fig. S2) .
DNA Damage-Repair Proteins Coimmunoprecipitate with Dynein.
Next we asked whether an antibody against the MT motor protein dynein could coimmunoprecipitate the DNA damage-repair proteins. As shown in Fig. 4 , we observed specific variable coimmunoprecipitation of the eight DNA damage-repair proteins with dynein both in the absence of any drug and after treatment of A549 cells with doxorubicin or vincristine. The dynein immunoprecipitation depleted dynein but did not deplete Mre11 or ATM, indicating only a small fraction of these proteins is associated with dynein at any given time (Fig. S3) . The latter finding is consistent with the experiments showing prominent fractionation/localization of these DNA repair proteins in the nucleus, where they have primary functions. Additionally, consistent with this, reciprocal coimmunoprecipitations did not in most cases precipitate dynein because only a small fraction of each DNA repair protein is bound to dynein at any one time (Fig. S3) . These results further support the hypothesis that trafficking of DNA damage-repair proteins on MTs could be susceptible to MTAs.
Paclitaxel Treatment Results in Higher and Sustained Levels of γ-H2AX
Protein in A549 and MCF7 Cells Treated with Radiation. To further investigate the relationship between the repair of damaged DNA and MT integrity, we asked if a MTA could prolong the effect of DNA damage caused by radiation. To do this, we quantitated the levels of γ-H2AX, a phosphorylated form of H2AX considered an indicator of DNA damage, in A549 and MCF7 cells pretreated with 200 nM paclitaxel and irradiated with 10 Gy. As shown in Fig. 5 , in control cells treated with only radiation, the levels of γ-H2AX had fallen substantially by 2 h and had nearly disappeared at 4 h. However, in cells treated with paclitaxel, γ-H2AX levels remained high, with substantial amounts of γ-H2AX still present at 4 and 8 h. This finding further confirmed the hypothesis that DNA damage-repair proteins traffic to the nucleus on MTs and that transport is hampered by MTAs. doxorubicin or 4 μM etoposide. Subsequently, the DDA was removed but the cells were maintained in vincristine for an additional 1, 2, 4, 6, or 8 h to monitor the levels and rate of disappearance of γ-H2AX. Control cells were treated similarly with the DDA but did not receive vincristine. As in the preceding experiments with paclitaxel and radiation, Figs. 6 and 7 show that vincristine resulted in γ-H2AX levels that were maintained above basal levels longer compared with the results in control cells treated only with the DDA for 4 h. Thus, again, disruption of MTs, this time using vincristine instead of paclitaxel, resulted in more sustained DNA damage, supporting the necessity for intact MTs to facilitate intracellular trafficking of DNA repair proteins to the nucleus. As expected, total H2AX protein levels were not affected by drug treatment. The graphs in Fig. 6B quantitate multiple experiments, with γ-H2AX levels normalized to GAPDH, and the starting level arbitrarily set at 1 for the doxorubicin-treated cells (DOX). The plots illustrate the more rapid disappearance of γ-H2AX levels in cells treated only with doxorubicin.
Proteomic Analysis of Dynein Immunoprecipitates Identifies Additional
DNA Damage-Repair Protein Candidates. Finally, recognizing that many other proteins are involved in repair of DNA damage, we performed a proteomic analysis of a dynein immunoprecipitate to identify, in a preliminary way, candidate proteins that might also traffic on MTs. The proteins identified are summarized in Table S2 . As expected, a diverse group of DNA damage-repair proteins were identified as protein candidates whose trafficking might be impaired, suggesting that impairing MT trafficking is likely to have broad consequences.
Discussion
MTAs, first introduced into the clinic in the late 1950s, are widely used in the therapy of cancer. Given the importance of MTs in cell division and the widely accepted concept that cancer cells divide more rapidly than normal cells, it has been generally assumed that MTAs mediate cytotoxicity by interfering with mitosis (1, 2). Elegant in vitro and preclinical data have demonstrated time and again that MTAs lead to mitotic arrest and in turn cell death (5, (7) (8) (9) (10) (11) (12) . Arrest in mitosis as the mechanism that leads to cell death is possible in these preclinical models because their doubling times range from a few hours to at most a few days, and even brief drug exposures are likely to encounter a substantial fraction of cells traversing through mitosis. However, most human tumors have doubling times of 30-60 d or longer (3, 5) , making it difficult-indeed almost impossible-to explain how mitotic arrest could be the mechanism of action when MTAs are administered to patients. We have proposed that rather than mitotic arrest, the principal mechanism of action of MTAs in a clinical setting is interference with intracellular trafficking during interphase (3, 4) . Key to this concept is identification of the critical proteins whose impaired trafficking on MTs leads to cytotoxicity. A straightforward example is provided by docetaxel and cabazitaxel, the only two "cytotoxic" agents approved in prostate cancer (13, 14) . Given the often very indolent nature of prostate cancer, it is difficult to argue that mitotic arrest is the mechanism of action for docetaxel and cabazitaxel in this disease (15) (16) (17) . Instead, it is increasingly accepted that interference with trafficking of the androgen receptor is the mechanism of action (18, 19) , a concept reinforced by the demonstration of tumors previously thought to be "androgen independent" that in fact continue to be very dependent on androgens (20) (21) (22) . Considering combinations used in the therapy of a variety of cancers, we realized they frequently included a DDA and a MTA (Table S1 ). Although this finding might be fortuitous or reflect the drugs available in oncology during the past five decades, the possibility this was other than a chance occurrence intrigued us. Turning to the paradigm that one must identify critical proteins whose function requires intact MTs to explain the efficacy of MTAs in a given cancer, we postulated and set out to prove that the crucial proteins affected by the MTAs in these combinations might be ones involved in DNA repair, and that by inhibiting their trafficking, MTAs could enhance the damage inflicted by the DDA. The data presented unequivocally demonstrate nine proteins involved in the repair of DNA damage associating with dynein and with MTs, and that by interfering with their trafficking, MTAs prolong DNA damage. We thus nominate these nine proteins to what should become a growing list of crucial proteins trafficking on MTs. For some of these proteins (23) (24) (25) (26) , an association with or trafficking on MTs has been previously reported and the present data corroborate and extend those observations (27) . We demonstrate effects consistent with our hypothesis using multiple cell lines, different methodologies, and both vincristine and paclitaxel. Cytoplasmic retention of proteins that repair DNA occurs with the addition of vincristine and paclitaxel in adherent A549 and MCF7 cells, as well as four nonadherent Burkitt's lymphoma cell lines and also in SKOV3 cells. That the retention is caused by interfering with MTs and is not a consequence of cell cycle arrest is supported by the results with the AKI (VX680) that achieved similar G 2 M arrest but had no effect on the intracellular distribution of the proteins that repair DNA damage. Additionally, taking advantage of the slower transit through the cell cycle that occurs when SKOV3 cells are deprived of serum, we show that despite reducing the number of cells in "mitosis," vincristine still leads to cytoplasmic retention of the DNA damage-repair proteins. Coimmunoprecipitation of the DNA damage-repair proteins with the MT motor protein dynein is consistent with dynein-mediated nuclear trafficking and is supported by the colocalization with tubulin seen by immunofluorescence. We note that, as we have previously shown for p53 (28) , association with dynein occurred even in the presence of vincristine, indicating that intact MTs, although essential for trafficking, are not needed for the interaction with dynein that likely occurs in the cytoplasm before "loading" onto MTs. Functionally, the observation that more sustained levels of γ-H2AX are achieved when vincristine or paclitaxel is added to radiation or a DDA provides evidence that interfering with MT-trafficking can augment DNA damage, given that γ-H2AX is considered a surrogate of the extent of DNA damage (29, 30) . This finding then provides a likely explanation for why combinations involving a MTA and a DDA have emerged "empirically" as active combinations in the majority of cancers. Our choice of which proteins involved in the repair of DNA damage to study was guided in large part by the availability of antibodies that worked well on immunoblots or immunofluorescence in A549 cells. Although many of these proteins have been implicated in the repair of radiation, as well as doxorubicin-and etoposide-induced DNA damage (31-34), we do not mean to imply they were all actively involved in the settings we examined. Nevertheless the experiments conducted with vincristine without a DDA, the dynein immunoprecipitation, and the immunolocalization all confirm the importance of intact MTs in intracellular trafficking of these proteins, and their association with MTs as well as dynein, the motor protein responsible for trafficking to the nucleus. Furthermore, we would expect additional proteins would be involved, as shown by our preliminary proteomic analysis.
Fifty years after the introduction of MTAs into clinical oncology, their mechanism of action in human tumors is becoming increasingly clear. To the androgen receptor, we now add numerous proteins involved in the repair of DNA damage as crucial proteins whose function is interdicted by inhibiting trafficking on MTs, resulting in prolonged DNA damage when used in combination with a DDA. We would anticipate that further inquiries should identify additional essential proteins and provide greater insight into tumor biology. Given their central role in the therapy of cancer, MTAs will continue to be used widely in combinations, both with "classic cytotoxic agents" and likely with "targeted therapies." We suggest that to make their use in combinations more rational, one should seek to identify the crucial proteins whose trafficking is disrupted. In this way it may be possible to go beyond additivity and instead reach for synergy.
Materials and Methods
Cell Lines and Reagents. CA46, DG-75, Ramos, ST486 (Burkitt's lymphoma), A549 (lung carcinoma), and MCF7 (breast carcinoma) cell lines were obtained from the American Type Culture Collection. The SKOV3 (ovarian carcinoma) cell line was obtained from the NCI-60 Drug Screen. Doxorubicin, vincristine, and etoposide were purchased from Sigma, and VX-680 (Tozasertib) was obtained from Chemietek. Protein Analysis in Nuclear and Cytoplasmic Fractions. Nuclear (N) and cytoplasmic (C) fractions were generated according to the protocol of the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo Scientific). Aliquots of whole-cell lysates or 10% of the volume of N or C fractions were separated by SDS/PAGE. Blots were incubated in antibodies discussed in SI Materials and Methods. This process was followed by IRDye infrared secondary antibodies (LiCor) and expression quantitated using the Odyssey Infrared Imager (LiCor) (35) . The percentage of cytoplasmic retention is indicated and calculated as [C/(C+N)] × 100%.
Drug Treatment. A549 cells were cultured for 24 h without drug or treated with either vincristine or the AKI VX-680 (Tozasertib) and then treated or not with doxorubicin. SKOV3 cells were cultured in RPMI in the presence or absence of serum for 48 h (6) before treatment with or without 100 nM vincristine for an additional 24 h, with or without serum. Nuclear and cytoplasmic fractions were prepared as described or cells were further processed for flow cytometry (36) . Mitotic cells were quantitated by two-variable analysis (37), using an FITC-labeled antiphospho histone H3 (Ser10) antibody (Cell Signaling).
Treatment of Cells with MTA or DDAs and Washout of DNA-Damaging Agent. A549 or MCF7 cells were either pretreated with 100 nM vincristine (VCR) for 24 h before a 4 h treatment with a combination of either VCR and 200 ng/mL doxorubicin or VCR and 4 μM etoposide, followed by washout of the DDA for either 0, 1, 2, 4, 6, or 8 h, in the presence of VCR. Control cells were either untreated or treated with 200 ng/mL doxorubicin or 4 μM etoposide for 4 h before washout of the DDA for identical time periods. Cells were harvested at 4°C, in 20 mM Tris pH7.5, 150 mM NaCl, 1 mM EDTA, 1% TX-100, with protease (aprotinin, Sigma, and cOmplete Mini, EDTA-free, Roche) and phosphatase inhibitors (PhosSTOP, Roche), frozen, and sonicated before SDS/PAGE. Western blots were probed with antibodies for γ-H2AX, total H2AX, or GAPDH, followed by IRDye infrared secondary antibodies (LiCor) and expression quantitated using the Odyssey Infrared Imager (LiCor) (35) .
Immunofluorescence. A549 cells were fixed in either ice-cold 100% methanol for 8 min at −20°C, or in 4% (vol/vol) paraformaldehyde for 30 min at 22°C, followed by 100% methanol for 8 min at 20°C, or in 4% (vol/vol) paraformaldehyde for 15 min at 22°C, followed by 0.3% TX-100 for 60 min. Cells were processed for immunofluorescence microscopy with modifications of previously described methods (35, 38) and the antibodies used are described in SI Materials and Methods.
Dynein Immunoprecipitation. Coimmunoprecipitations in A549 cells were modified from previously described methods (28) . Blots were probed with anti-dynein, anti-Bim, and other antibodies as described above. Additional procedures are described in SI Materials and Methods.
Proteomics. Cell lysate was immunoprecipitated with anti-dynein conjugated to M-270 Epoxy Dynabeads (Life Technol) and analyzed by mass spectrometry as previously described (39) and described in SI Materials and Methods.
